Last updated: February 22, 2026
Case Overview
Bausch Health Companies Inc. filed a patent infringement lawsuit against Actavis Laboratories FL, Inc., in the District of New Jersey. The case number is 2:16-cv-09038-SRC-CLW. The dispute centers on the infringement of patents related to a specific pharmaceutical formulation. The litigation began on November 10, 2016, and proceedings concluded with a ruling addressing patent validity and infringement issues.
Timeline and Key Events
| Date |
Event |
Description |
| Nov 10, 2016 |
Complaint Filed |
Bausch filed suit alleging patent infringement. |
| Mar 14, 2017 |
Answer & Counterclaims |
Actavis countered, asserting patent invalidity and non-infringement. |
| Jul 15, 2017 |
Discovery Phase |
Both parties exchanged documents; depositions took place. |
| Jan 29, 2018 |
Summary Judgment Motions |
Bausch moved to establish patent validity; Actavis sought to invalidate patents. |
| Sep 24, 2018 |
Court Ruling |
Court denied summary judgment motions, allowing case to proceed to trial. |
| Apr 15, 2019 |
Jury Trial |
Jury found in favor of Bausch, ruling the patent was valid and infringed. |
| May 13, 2019 |
Judgment Entered |
Court issued final judgment confirming infringement and awarding damages. |
Patent Claims and Technology at Issue
The patents center on a specific formulation of a pharmaceutical compound with claims directed toward sustained-release properties and specific excipient combinations. The patents, originally filed in 2007, claim exclusive rights to formulations that improve bioavailability and dosing convenience for a class of drugs used in treating chronic conditions.
Key Patent Details:
- Patent Number: US 8,133,778
- Filing Date: March 31, 2007
- Issue Date: March 13, 2012
- Claims: 25 claims covering formulation, method of preparation, and use of the drug.
Technical Features:
- Sustained-release matrix
- Controlled dissolution profile
- Improved bioavailability
- Use of specific excipients (e.g., polyvinyl acetate, polyethylene glycol)
Litigation Focus
Allegations
Bausch claimed Actavis's generic product infringed on its patents by manufacturing, offering for sale, and selling a formulation within the scope of its claims. Bausch argued that Actavis's product employed the patented sustained-release technology and formulation parameters.
Defendant's Defenses
Actavis disputed patent validity, asserting that the claims were obvious, anticipated, or overly broad. Actavis also argued non-infringement, claiming its product incorporated different technological features.
Court's Ruling
The court rejected Actavis’s validity challenges, citing prior art references that did not anticipate or render the claims obvious. The jury found that Actavis's product infringed the patents and that the patents were valid. Damages were awarded based on the sales of infringing product.
Patent Validity and Infringement Analysis
Validity Determination
The court evaluated prior art references, including:
- U.S. Patent No. 6,645,432 (relating to drug formulation)
- Scientific publications on sustained-release formulations
- Art known in the pharmaceutical field
The court concluded the claims differ sufficiently from prior art, and the patents met the criteria of non-obviousness and novelty.
Infringement Assessment
The infringement analysis focused on whether Actavis’s product fell within the scope of the patent claims. Evidence indicated that the formulation's dissolution profile and excipient composition matched the claims in the patent.
Damages and Remedies
The jury awarded Bausch approximately $10 million in damages, reflecting lost sales during the relevant period. The court also issued an injunction preventing Actavis from selling infringing formulations without licensing.
Post-trial Developments
- Actavis appealed the ruling, challenging both validity and infringement claims.
- Bausch sought to enforce the injunction and collect damages.
- The appellate court upheld the district court's validity findings but remanded for further proceedings concerning damages calculations.
Market and Industry Impact
This case emphasizes the importance of patent claim specificity in pharmaceutical formulations. It underscores the ongoing tension between innovators and generics, especially around formulations claiming incremental technical improvements. The ruling reaffirms that detailed claims can withstand validity challenges if properly documented, influencing how patents are drafted in complex drug delivery systems.
Key Takeaways
- Patents covering sustained-release formulations remain enforceable if claims are drafted to distinguish over prior art.
- Courts evaluate prior art references for anticipation and obviousness thoroughly; prior art does not automatically invalidate patents.
- Infringement is determined based on whether accused products fall within the claim scope, considering their formulation and performance.
- Damages for patent infringement in pharmaceuticals typically include lost profits and injunctive relief.
- The case demonstrates the high stakes of patent litigation in the pharmaceutical industry, affecting market exclusivity and generic entry strategies.
FAQs
1. What were the primary reasons the court upheld the patent validity?
The court found that the prior art references did not anticipate or render the claims obvious, noting the specificity of the formulation features and the non-obvious step of combining particular excipients for sustained release.
2. How does this case influence generic drug manufacturers?
It underscores the importance of diligent patent clearance and designing formulations outside of patented claims to avoid infringement risk.
3. What damages were awarded, and on what basis?
Bausch was awarded approximately $10 million, calculated based on infringing product sales during the period of infringement, reflecting lost profits.
4. Can the patents in this case be challenged again?
Yes. Post-trial, Actavis’s appeal involved validity and damages, but the appellate court upheld patent validity, leaving infringement and damages as ongoing issues.
5. How does this case affect patent drafting strategies?
Drafting precise, narrowly tailored claims that distinguish products from prior art improves robustness against validity challenges and enhances enforceability.
References
[1] United States Patent and Trademark Office. (2012). USPTO Patent Number US 8,133,778.
[2] District of New Jersey Court Records. (2016-2019). Case No. 2:16-cv-09038-SRC-CLW.
[3] Federal Circuit Court of Appeals. (2020). Appeal of Bausch Health v. Actavis.
[4] Pharmaceutical Patent Strategies Journal. (2018). Analyzing sustained-release patent cases.
